EUVIMEDEUVIMED entdecken
Open Access

Autologous Transplant or CAR ‐T as Consolidation Options in MYC Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments

Fateeha Furqan iD, Kwang W Ahn, Manmeet Kaur iD, Jinalben Patel, Stephen Ansell iD, Farrukh T Awan iD, John Baird iD, Evandro Bezerra, Umar Farooq, Henry Fung, Arushi Khurana iD, Lazaros Lekakis und 13 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27687 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Fateeha Furqan und 24 weiteren Autor:innen. Beteiligte Einrichtung: BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Salvage Therapy, Lymphoma, Large B-Cell, Diffuse, Hematopoietic Stem Cell Transplantation, Immunotherapy, Adoptive. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although recent studies have demonstrated the efficacy of chimeric antigen receptor T‐cell (CAR‐T) therapy in relapsed large B‐cell lymphoma (LBCL) with MYC rearrangement (R‐MYC), the data comparing CAR‐T to autologous hematopoietic cell transplant (auto‐HCT) in such patients who achieve a complete or partial response (CR/PR) after salvage therapies are limited. We compared the clinical outcomes of patients with R‐MYC LBCL (including double and triple hit lymphomas) who underwent CAR‐T or auto‐HCT after achieving a CR/PR with salvage therapies using the Center for International Blood & Marrow Transplant Research registry. Among the 252 patients (auto‐HCT = 98, CAR‐T = 154), relative to auto‐HCT, CAR‐T was associated with significantly lower overall survival (OS) (Hazard Ratio [HR] 2.09, 95% CI 1.38–3.15, p < 0.001) on multivariate analysis. There were no differences in progression‐free survival (PFS) (HR 1.21, 95% CI 0.81–1.8 p = 0.36), risk of relapse (HR 1.1, 95% CI 0.71–1.69 p = 0.68), nonrelapse mortality (NRM) (HR 1.74, 95% CI 0.64–4.7 p = 0.28) while the post‐relapse survival was longer in auto‐HCT relative to CAR‐T (HR 1.93, 95% CI 1.21–3.06 p = 0.01). On propensity score matched analysis accounting for differences in characteristics across the two cohorts, we detected no significant differences in OS (HR 1.72, 95% CI 0.92–3.21 p = 0.09), PFS (HR 1.04, 95% CI 0.64–1.68 p = 0.88), NRM (HR 1.22, 95% CI 0.35–4.2 p = 0.76), relapse (HR = 0.93, 95% CI 0.54–1.6 p = 0.8) and post‐relapse survival (HR 2.25, 95% CI 0.98–5.17, p = 0.06). These data, although retrospective, support consideration for auto‐HCT in patients with R‐MYC LBCL who achieve a CR/PR after salvage therapies, particularly in regions with no or limited access to CAR‐T.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Salvage TherapyLymphoma, Large B-Cell, DiffuseHematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveProto-Oncogene Proteins c-mycReceptors, Chimeric AntigenHumansMaleFemaleMiddle AgedAgedTransplantation, AutologousAdultRetrospective StudiesGene RearrangementRemission Induction

Stichwörter der Autor:innen

CAR T‐cell therapyMYC rearrangementautologous stem cell transplantdouble hit lymphomahigh grade lymphoma

Substanzen

Proto-Oncogene Proteins c-mycMYC protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.

ORCID-Profile: Fateeha Furqan, Manmeet Kaur, Stephen Ansell, Farrukh T Awan, John Baird, Arushi Khurana, Allison Winter, Mazyar Shadman, Alex Herrara

Förderung

  • NCI NIH HHS

Zitieren

APA

Furqan, F., Ahn, K. W., Kaur, M., Patel, J., Ansell, S., Awan, F. T., Baird, J., Bezerra, E., Farooq, U., Fung, H., Khurana, A., Lekakis, L., Lutfi, F., McCarty, J., Mukherjee, A., Nath, R., Romancik, J., Schuster, S. J., Smith, M., …, & Hamadani, M. (2025). Autologous Transplant or CAR ‐T as Consolidation Options in MYC Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments. American Journal of Hematology. https://doi.org/10.1002/ajh.27687

Vancouver

Furqan F, Ahn KW, Kaur M, Patel J, Ansell S, Awan FT, et al. Autologous Transplant or CAR ‐T as Consolidation Options in MYC Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments. American Journal of Hematology. 2025. doi:10.1002/ajh.27687

BibTeX
@article{Furqan2025,
  author = {Furqan, Fateeha and Ahn, Kwang W and Kaur, Manmeet and Patel, Jinalben and Ansell, Stephen and Awan, Farrukh T and Baird, John and Bezerra, Evandro and Farooq, Umar and Fung, Henry and Khurana, Arushi and Lekakis, Lazaros and Lutfi, Forat and McCarty, John and Mukherjee, Akash and Nath, Rajneesh and Romancik, Jason and Schuster, Stephen J and Smith, Melody and Winter, Allison and Turtle, Cameron and Sauter, Craig and Shadman, Mazyar and Herrara, Alex and Hamadani, Mehdi},
  title = {Autologous Transplant or CAR ‐T as Consolidation Options in MYC Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27687}
}
Kostenlos starten →